Home›Oncology› CAR T-cell therapies targeting specific antigens show potential for treating pediatric CNS tumors
CAR T-cell therapies targeting specific antigens show potential for treating pediatric CNS tumorsNew CAR T-cell therapies show promise for pediatric brain tumors
Frontiers in MedicinePublished July 26, 2026DOI ↗Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Note that CAR T-cell therapies targeting specific antigens show potential but face hurdles like antigen escape.
This narrative review synthesizes evidence from 18 studies, including preclinical models, translational research, and 12 registered clinical trials, to evaluate CAR T-cell therapies targeting antigens like B7-H3, GD2, HER2, IL13Rα2, and EphA2 in pediatric CNS tumors. The review highlights that preclinical models of medulloblastoma, DIPG, ependymoma, and high-grade gliomas showed robust and specific tumor regression.
Clinical data from a phase 1 trial for ICV B7-H3 targeted therapy in patients with DIPG reported a median survival of 19.8 months, with 3 out of 21 patients surviving more than 40 months. Additionally, GD2-CAR T-cell therapy in H3K27 M-mutant gliomas showed partial clinical responses, while HER2-targeted locoregional therapy reported no dose-limiting toxicities.
The authors note several significant limitations to current progress, including tumor heterogeneity, antigen escape, and the immunosuppressive tumor microenvironment. While CAR T-cell therapy shows promise for improving outcomes in pediatric brain tumors, clinical translation is currently challenged by these factors and risks of neurotoxicity or encephalopathy.
How this fits prior evidence
This narrative review addresses a gap in current evidence regarding specific CAR T-cell targets for pediatric CNS tumors. It expands upon the finding that intracranial immunotherapy delivery does not improve survival for pediatric high-grade glioma compared to systemic administration, by highlighting specific antigens like B7-H3 and GD2. Furthermore, it relates to findings on multitarget designs as a strategy to overcome resistance in other malignancies, though current clinical translation for pediatric cases remains limited by antigen escape and neurotoxicity.
Treating childhood brain tumors like medulloblastoma or high-grade glioma is incredibly difficult. New research into CAR T-cell therapy offers a different approach by training the body's immune cells to hunt and attack specific markers on cancer cells.
In early studies, these engineered cells showed strong results in shrinking tumors in laboratory models. In a clinical trial for a specific brain tumor called DIPG, patients receiving this treatment saw a median survival of 19.8 months, with some living over 40 months. Other trials also showed partial responses and cases where the treatment was well-tolerated without severe side effects.
While these results are encouraging, there are hurdles to overcome. Some patients experienced neurotoxicity or encephalopathy, which are conditions affecting brain function. Additionally, the complex environment of a tumor can sometimes shield cancer cells from the immune system. Because much of this data comes from early trials and lab models, more research is needed to see how these therapies perform in larger groups.
What this means for you:
CAR T-cell therapy shows promise for shrinking tumors and extending life in children with brain cancer.
Common questions
What is CAR T-cell therapy?
It is a treatment where the body's immune cells are engineered to recognize and attack specific targets on cancer cells. In these studies, researchers targeted markers like B7-H3, GD2, HER2, IL13Rα2, and EphA2 to treat pediatric brain tumors.
How well did it work for patients with DIPG?
In a phase 1 trial for children with DIPG, the median survival was 19.8 months. Out of 21 patients in that specific study, three individuals survived more than 40 months.
Are there any known side effects?
Some patients receiving GD2-CAR T-cell therapy experienced neurotoxicity and encephalopathy, which are conditions affecting the brain. However, another trial using HER2-targeted therapy reported no dose-limiting toxicities.
Pediatric brain tumors are the leading cause of cancer-related mortality in children, and current standard therapies like surgery, radiotherapy, and chemotherapy offer limited survival benefits and significant long-term morbidity. Chimeric antigen receptor (CAR) T-cell therapy is a transformative treatment for hematologic malignancies and is now being explored for pediatric brain tumors. This review summarizes the latest advances, preclinical and clinical findings, challenges of CAR T-cell therapy, and future directions in pediatric neuro-oncology. 18 studies that met the eligibility criteria were selected, consisting of preclinical models, early-phase clinical trials, and translational studies. A registry search of central nervous system (CNS) tumor trials from Clinicaltrials.gov, ISRCTN, and ANZCTR identified 12 active or completed interventional trials of CAR T-cell therapy in patients with CNS tumors, their eligibility criteria and parameters were compared. Preclinical studies consistently demonstrate that CAR T-cells targeting antigens such as B7-H3, GD2, HER2, IL13Rα2, and EphA2 can induce robust and specific tumor regression in models of medulloblastoma, diffuse intrinsic pontine glioma (DIPG), ependymoma, and high-grade gliomas. On the other hand, B7-H3 is a pan-pediatric target due to its high expression in multiple CNS tumors, including medulloblastoma, ependymoma, and glioma, whereas GD2 is highly relevant for H3K27M-mutant diffuse midline gliomas. Early-phase clinical trials confirm that CAR T-cells can traffic to CNS tumors, infiltrate tumor tissue, and mediate tumor regression. The ICV B7-H3 phase 1 trial in DIPG achieved noteworthy results, with a median survival of 19.8 months across 21 patients and 3 patients surviving more than 40 months. GD2-CAR T-cell therapy in H3K27 M-mutant gliomas showed partial clinical responses, with neurotoxicity and encephalopathy observed, whereas the HER2-targeted locoregional therapy showed no dose-limiting toxicities. Future interventions such as multi-antigen targeting, combinatorial CAR designs, and enhanced cytokine signaling are being developed to improve efficacy and safety. A comparison of 12 registered pediatric CAR T-cell trials showed heterogeneity in eligibility criteria, including age ranges, performance status thresholds, H3K27M mutation requirements, and geographic concentration bias. CAR T-cell therapy holds significant promise for improving outcomes in pediatric brain tumors, but its clinical translation is challenged by tumor heterogeneity, antigen escape, neurotoxicity, and the immunosuppressive tumor microenvironment.
